Everence Capital Management Inc. Purchases Shares of 9,800 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Everence Capital Management Inc. purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 4th quarter, Holdings Channel reports. The firm purchased 9,800 shares of the specialty pharmaceutical company’s stock, valued at approximately $302,000.

Other large investors also recently made changes to their positions in the company. Pacer Advisors Inc. boosted its holdings in shares of Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after acquiring an additional 883,380 shares in the last quarter. Natixis Advisors L.P. boosted its holdings in shares of Collegium Pharmaceutical by 152.9% in the third quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock valued at $1,215,000 after acquiring an additional 32,865 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Collegium Pharmaceutical by 32.7% in the third quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after acquiring an additional 67,439 shares in the last quarter. Barclays PLC boosted its holdings in shares of Collegium Pharmaceutical by 16.9% in the third quarter. Barclays PLC now owns 39,593 shares of the specialty pharmaceutical company’s stock valued at $886,000 after acquiring an additional 5,713 shares in the last quarter. Finally, Ritholtz Wealth Management bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $286,000.

Collegium Pharmaceutical Trading Down 1.9 %

Shares of NASDAQ:COLL opened at $34.77 on Friday. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of 29.47 and a beta of 1.03. Collegium Pharmaceutical, Inc. has a 1-year low of $20.83 and a 1-year high of $40.95. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17. The company has a 50 day moving average price of $36.82 and a 200 day moving average price of $30.72.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The firm had revenue of $149.75 million during the quarter, compared to analyst estimates of $147.66 million. On average, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

COLL has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Friday, March 29th. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, February 26th. Piper Sandler restated an “overweight” rating and set a $39.00 target price (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Finally, Jefferies Financial Group restated a “hold” rating and set a $37.00 target price (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.